PRAMEF11 inhibitors represent a specialized class of chemical compounds designed to modulate the activity of the PRAMEF11 protein, which is part of the PRAME family of proteins. PRAME proteins (Preferentially Expressed Antigen in Melanoma) belong to a larger group of leucine-rich repeat (LRR) proteins, characterized by their involvement in diverse cellular processes, including cell cycle regulation and protein-protein interactions. PRAMEF11, a specific member of this family, is thought to participate in molecular pathways linked to cell proliferation and differentiation, which are crucial for maintaining the balance between cell growth and apoptosis. Inhibitors targeting PRAMEF11 work by binding to specific regions of the protein, usually at the active or allosteric sites, leading to a reduction or alteration in its activity. These inhibitors can be categorized based on their structural motifs, which vary depending on the nature of the protein binding site, with some showing high specificity for PRAMEF11, while others may affect multiple PRAME family members.
The design of PRAMEF11 inhibitors often involves computational modeling to predict the most favorable interactions between the inhibitor and the protein. Structural features such as hydrogen bonding, hydrophobic interactions, and van der Waals forces play significant roles in the stability and affinity of these inhibitors. In terms of chemical composition, PRAMEF11 inhibitors can vary from small organic molecules to larger peptide-based inhibitors, each designed with the goal of maximizing specificity and minimizing off-target effects. Advanced screening techniques, such as high-throughput screening and molecular docking, are employed to identify potential PRAMEF11 inhibitors, followed by extensive biochemical characterization to determine their binding affinities, selectivity, and mechanism of action. The continuing refinement of PRAMEF11 inhibitors through structure-activity relationship (SAR) studies enhances our understanding of the protein's function at a molecular level and contributes to broader research on LRR-containing proteins.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound could induce DNA demethylation specifically at the promoter region of the PRAMEF11 gene, leading to a decrease in gene expression by interfering with transcriptional activation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid may lead to hyperacetylation of histones associated with the PRAMEF11 gene, which could result in the downregulation of its transcription by altering chromatin accessibility. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
As a cytosine analog, 5-Aza-2′-Deoxycytidine may incorporate into PRAMEF11's DNA during replication, inhibiting DNA methyltransferases and thereby reducing PRAMEF11 expression by promoter demethylation. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
This diterpene triepoxide could inhibit the expression of PRAMEF11 by obstructing the binding of essential transcription factors necessary for PRAMEF11 gene transcription. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
By binding to retinoic acid receptors, Retinoic Acid could downregulate PRAMEF11 expression as part of a concerted change in gene expression that guides cellular differentiation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin could decrease PRAMEF11 expression by stalling the mTOR signaling pathway, which is crucial for protein synthesis and cell cycle progression, thereby reducing the protein synthesis machinery available for PRAMEF11. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
By intercalating into DNA, Doxorubicin could prevent the transcriptional machinery from accessing the PRAMEF11 gene, thereby decreasing its expression. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin could downregulate PRAMEF11 by inhibiting the activity of NF-κB, a transcription factor known to be involved in the expression of various genes, potentially including PRAMEF11. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A may decrease PRAMEF11 expression by specifically inhibiting class I and II histone deacetylases, leading to an open chromatin structure that hinders the transcription of PRAMEF11. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $150.00 $286.00 $479.00 $1299.00 $8299.00 $915.00 | 22 | |
This isothiocyanate could decrease PRAMEF11 expression by selectively inhibiting histone deacetylases, which would result in chromatin remodeling and subsequent transcriptional repression of PRAMEF11. | ||||||